United States · FDA National Drug Code directory

Adalimumab-ryvk

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference: 82009-156_e837767b-482a-487d-9d35-4516a8c25b3e
Product NDC: 82009-156
Form: KIT
Composition / generic term: adalimumab-ryvk
Labeler: Quallent Pharmaceuticals Health LLC
Marketing category: BLA
Marketing start / end (source format): 20240522
Source listing expiry: 20271231

Source-listed ingredients

Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.

These values do not establish equivalence or a dose recommendation.

Packages

2 KIT in 1 CARTON (82009-156-22) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY (82009-157-11) / .4 mL in 1 SYRINGE * .4 mL in 1 POUCH (65517-0002-1) · 82009-156-22

Source and coverage

Open FDA National Drug Code directory →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →